# Germany Allergy Immunotherapy Market

> Germany Allergy Immunotherapy Market Research Report: By Type (Subcutaneous Immunotherapy, Sublingual Immunotherapy, Oral Immunotherapy), By Product (Allergen Extracts, Conventional Immunotherapy, Biologics), By Indication (Allergic Rhinitis, Allergic Asthma, Atopic Dermatitis, Food Allergies) andBy Patient Type (Pediatric, Adult, Geriatric)- Forecast to 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 9.43%
- **2018:** $ 266 Million
- **2024:** $ 277.34 Million
- **2035:** $ 747.45 Million
- **Key Players:** Allergopharma (DE), Boehringer Ingelheim (DE), Merck KGaA (DE), Stallergenes Greer (FR), Anergis (CH), ALK-Abello (DK), Novartis (CH), Roxall (DE), TheraP (DE)

**Report ID:** MRFR/HC/54527-HCR · **Pages:** 200 · **Author:** Nidhi Mandole · **Last Updated:** May 12, 2026

**URL:** https://www.marketresearchfuture.com/reports/germany-allergy-immunotherapy-market-56293

---

## Market Summary

**Germany Allergy Immunotherapy Market Overview****:**

**As per MRFR analysis, the Germany Allergy Immunotherapy Market Size was estimated at 266 (USD Million) in 2023. The Germany Allergy Immunotherapy Market Industry is expected to grow from 285.5(USD Million) in 2024 to 571 (USD Million) by 2035. The Germany Allergy Immunotherapy Market CAGR (growth rate) is expected to be around 6.504% during the forecast period (2025 - 2035).**

**Key****Germany Allergy Immunotherapy Market****Trends Highlighted**

An increasing prevalence of allergies and a growing awareness of available treatment options are driving notable trends in the Germany Allergy Immunotherapy Market. The country has experienced an increase in the number of individuals seeking medical attention and treatment for allergic conditions, including hay fever and dietary allergies. Health organizations' awareness campaigns have been instrumental in educating the public about the advantages of immunotherapy as a sustainable solution. Additionally, the German Federal Ministry of Health is actively advocating for the development of new treatment methods and formulations in the market by providing research funding and promoting innovative therapies. Germany presents substantial opportunities for exploration. There is a potential for the expansion of immunotherapy treatments that are customized to the unique needs of different age groups, given the high incidence of allergic diseases among minors and the aging population. The integration of digital health solutions, such as telemedicine and mobile health applications, offers opportunities to effectively manage treatment adherence and enhance patient engagement. Furthermore, it is anticipated that the demand for personalized treatment plans will increase as more healthcare providers implement personalized medicine tactics. Additionally, there has been a recent increase in the utilization of sublingual immunotherapy as a substitute for conventional injection techniques as a result of its convenience and patient comfort.Pharmaceutical companies and research institutions are increasingly collaborating to enhance the efficacy and safety profiles of their products, which is fostering a surge in research and development in this field. The Allergy Immunotherapy Market is poised to experience growth as the German healthcare system continues to develop, driven by these various developments.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Germany Allergy Immunotherapy Market Drivers**

Rising Allergy Incidence and Prevalence in Germany

Germany Allergy Immunotherapy Market Industry is experiencing substantial growth driven by the increasing incidence of allergies among the population. Research indicates that approximately 30% of adults and 40% of children in Germany suffer from allergic conditions, such as rhinitis and asthma, as reported by the National Allergy and Asthma Association. This surge in allergic reactions is attributed to environmental factors and lifestyle changes and signifies a growing demand for effective allergy treatments.Organizations such as the German Society for Allergology and Clinical Immunology (DGAKI) continue to emphasize the importance of Allergy Immunotherapy as a viable treatment modality. As more individuals seek long-term solutions to manage their allergies, the Germany Allergy Immunotherapy Market is projected to expand significantly over the coming years.

Advancements in Research and Development

The progress in Research and Development within the Germany Allergy Immunotherapy Market Industry is leading to the emergence of innovative therapies. Institutions like the Max Planck Institute and pharmaceutical companies are actively involved in developing new allergen-specific Immunotherapy treatments. Recent breakthroughs include the introduction of sublingual tablets and new adjuvants that enhance the efficacy of immunotherapy. This advancement is crucial as the German government invests heavily in healthcare R&D, allocating approximately 9.5% of its GDP towards innovative health solutions.These advancements not only diversify treatment options available to patients but also drive the growth of the Germany Allergy Immunotherapy Market.

Increase in Environmental Pollutants and Allergens

The growing levels of environmental pollutants in Germany, including high pollen counts and urban air quality challenges, are contributing to the rise in allergy-related conditions, thus impacting the Germany Allergy Immunotherapy Market Industry. Research from environmental agencies reveals that pollen exposure, particularly from trees, grasses, and weeds, has increased by 15% over the past decade, exacerbating allergic responses among the population.With cities like Berlin facing challenges regarding air quality, public health campaigns are promoting allergy management solutions, including immunotherapy. This trend towards public awareness and the seeking of treatment is likely to further fuel market growth.

Government Initiatives and Regulations Supporting Allergy Treatments

Government initiatives aimed at enhancing healthcare access and improving allergy management are significant drivers in the Germany Allergy Immunotherapy Market Industry. German health policies, such as the Health Modernization Act, which aims to improve patient access to new treatment technologies, are reshaping the landscape. The government encourages the use of Allergy Immunotherapy as a primary care option through subsidies and public health programs.According to the Federal Ministry of Health, patients diagnosed with allergies are now eligible for increased reimbursement rates for immunotherapy, making these treatments more accessible. As these policies continue to evolve, they will likely lead to increased adoption of Immunotherapy solutions across Germany.

**Germany Allergy Immunotherapy Market Segment Insights****:**

**Allergy Immunotherapy Market Type Insights**

The Germany Allergy Immunotherapy Market is increasingly segmented into various types, primarily focusing on Subcutaneous Immunotherapy, Sublingual Immunotherapy, and Oral Immunotherapy. Subcutaneous Immunotherapy, often viewed as the traditional approach, has gained traction for effectively treating a range of allergic conditions by administering allergens through injections, allowing the patient's immune system to build tolerance over time. Its established history and clinical efficacy contribute to its popularity in Germany, making it a prevalent choice among healthcare providers.On the other hand, Sublingual Immunotherapy offers a more patient-friendly alternative, as it involves placing allergen tablets or drops under the tongue. This method appeals to patients due to its ease of administration and the reduced need for medical visits, thus driving its adoption among those seeking less invasive treatment options. Meanwhile, Oral Immunotherapy is gaining attention as a novel treatment strategy, particularly for food allergies. Its growing acceptance signifies a shift in treatment paradigms, focusing on desensitizing individuals to specific allergens through controlled ingestion.This segment reflects innovation in the field of allergen management, catering to the increasing demand for effective solutions for food-related allergic reactions. As public awareness of allergies continues to rise in Germany, driven by changes in lifestyle and environmental factors, the demand for these immunotherapy types will likely expand, indicating significant growth potential. Challenges such as varying patient adherence and the necessity for consistent dosing may affect the market dynamics. Yet, the opportunities presented by advancements in immunotherapy research could enhance patient outcomes and satisfaction in the coming years.Thus, the Type segmentation in the Germany Allergy Immunotherapy Market not only highlights the diversity of treatment options available but also underscores the ongoing evolution of allergen management strategies in response to the growing prevalence of allergic conditions in the region.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Allergy Immunotherapy Market Product Insights**

The Germany Allergy Immunotherapy Market is characterized by a diverse range of products that are crucial for managing allergic conditions. A significant component of this market includes Allergen Extracts, which are essential for both diagnostic and therapeutic purposes, enabling tailored treatments for patients based on specific sensitivities. Conventional Immunotherapy remains a cornerstone in allergy management, providing long-term relief by gradually desensitizing patients to allergens, thus reducing the severity of allergic reactions. Additionally, the Biologics segment is gaining traction, offering innovative therapies that leverage biological processes to effectively target underlying immune responses.Given the increasing prevalence of allergies in Germany, driven by environmental factors and lifestyle changes, these product segments are pivotal in addressing the growing demand for effective treatment options. The market dynamics indicate that advancements in research and technology will continue to enhance the efficacy and safety of these products, contributing positively to the overall growth of the Germany Allergy Immunotherapy Market.

**Allergy Immunotherapy Market Indication Insights**

The Germany Allergy Immunotherapy Market is significantly influenced by various indications, with Allergic Rhinitis being one of the most prevalent conditions among the population, driven by environmental allergens such as pollen and dust mites. This segment is crucial as it impacts a large percentage of individuals, leading to increased healthcare utilization and demand for effective treatments. Allergic Asthma is another notable indication, where immunotherapy plays a vital role in managing symptoms and improving the quality of life for patients, particularly in urban areas with higher pollution levels.Atopic Dermatitis, characterized by chronic skin inflammation, is also gaining attention due to the rising incidence and awareness of skin allergies among the German population. Food Allergies remain a significant concern, particularly among children, as they pose serious health risks and complicate daily living. Overall, the segmentation within the Germany Allergy Immunotherapy Market indicates a diverse landscape, reflecting varying patient needs and treatment approaches, which collectively contribute to the growth and development of the industry.The increasing focus on personalized medicine and advances in immunotherapy techniques is expected to further enhance treatment outcomes across these indications.

**Allergy Immunotherapy Market Patient Type Insights**

The Germany Allergy Immunotherapy Market, categorized by Patient Type, showcases a diverse demographic that encompasses Pediatric, Adult, and Geriatric populations. The growing prevalence of allergies among children emphasizes the significance of the Pediatric segment, as early intervention through immunotherapy can greatly improve long-term health outcomes and quality of life. Furthermore, the Adult segment dominates the market due to the increasing awareness and availability of advanced treatments for allergic conditions, contributing to a larger share of patient populations seeking relief.In contrast, the Geriatric segment is emerging with a notable presence, as this age group tends to experience heightened allergy symptoms due to age-related factors, making targeted immunotherapy increasingly vital. Overall, the segmentation within the Germany Allergy Immunotherapy Market underlines a strategic focus on addressing the unique needs of these distinct patient groups, reflecting broader trends in healthcare that prioritize tailored treatment strategies for improved efficacy and patient satisfaction.

**Germany Allergy Immunotherapy Market Key Players and Competitive Insights****:**

The Germany Allergy Immunotherapy Market is witnessing significant advancements driven by an increasing prevalence of allergic diseases and a growing awareness of immunotherapy as a viable treatment. With a robust healthcare system and innovative biopharmaceutical companies, the market is characterized by a mix of established players and emerging firms, all vying to capture a growing share of the market. Competition is primarily fueled by ongoing research and development efforts aimed at creating more effective treatments, as well as a focus on patient-centered care and personalized medicine. The regulatory environment in Germany also plays a critical role in shaping the landscape of the allergy immunotherapy sector, as companies must navigate complex approval processes for their products while ensuring safety and efficacy.BioNTech SE has established itself as a strong player in the German Allergy Immunotherapy Market, leveraging its cutting-edge mRNA technology and commitment to research-driven solutions. The company's strengths lie in its ability to rapidly develop innovative therapies that cater to specific allergic responses, which is vital in addressing the diverse needs of patients suffering from various allergies. BioNTech SE's strong presence in Germany is bolstered by its collaborative partnerships with healthcare providers and research institutions, enabling it to facilitate clinical studies and accelerate the introduction of novel immunotherapy options. Furthermore, the company's expertise in immunology and advanced therapeutic platforms positions it favorably to compete in a market characterized by rapid technological advancements.Stallergenes Greer is another key player within the Germany Allergy Immunotherapy Market, recognized for its extensive portfolio of allergen immunotherapy products and services. With a focus on customizing treatment for patients, Stallergenes Greer offers a range of products, including subcutaneous and sublingual immunotherapy formulations, making them highly relevant in the German context where personalized patient care is paramount. The company’s market presence is significant due to its strong distribution network and established relationships with healthcare professionals, allowing it to effectively reach and cater to allergic patients across Germany. Additionally, Stallergenes Greer has engaged in strategic mergers and acquisitions that have expanded its capabilities and product offerings, enhancing its competitive edge in the market. With continuous investment in R&D, the company looks to innovate further in allergen immunotherapy, ensuring it remains a trusted choice for both healthcare providers and patients dealing with allergies in Germany.

**Key Companies in the Germany Allergy Immunotherapy Market Include:**

BioNTech SE

Stallergenes Greer

TheraBurst

Immunovative Therapies Ltd

Novartis AG

GlaxoSmithKline plc

Boehringer Ingelheim GmbH

Allergy Therapeutics plc

Rhinopharma

Anergis SA

Merck KGaA

Aimmune Therapeutics Inc.

Mylan N.V.

Allergopharma GmbH & Co. KG

UCB S.A.

**Germany Allergy Immunotherapy Market Industry Developments**

_In recent months, the Germany Allergy Immunotherapy Market has seen significant developments, particularly with companies like BioNTech SE and Novartis AG making strides in research and product offerings. In September 2023, Allergopharma GmbH & Co. KG expanded its portfolio with new immunotherapy products aimed at treating food allergies. Additionally, Merck KGaA announced advancements in biologics designed to enhance the efficacy of treatments for allergic diseases in August 2023. The market is also experiencing increased competition__,__with Stallergenes Greer and GlaxoSmithKline plc significantly investing in Research and Development to innovate their immunotherapy solutions. In terms of mergers, TheraBurst and Rhinopharma are reportedly in talks to consolidate their market positions, with discussions ongoing since October 2023. This consolidation trend reflects a larger movement in the sector to streamline operations and enhance treatment offerings for patients. Furthermore, as of 2022, the market valuation has shown robust growth, attributed to rising allergy incidences and increasing awareness about immunotherapy benefits among patients and healthcare providers in Germany. The focus on tailoring therapies to individual needs has also gained momentum, driving a new wave of product development in the sector._

**Germany Allergy Immunotherapy Market Segmentation Insights**

**Allergy Immunotherapy Market Type****Outlook**

**Subcutaneous Immunotherapy**

**Sublingual Immunotherapy**

**Oral Immunotherapy**

**Allergy Immunotherapy Market Product****Outlook**

**Allergen Extracts**

**Conventional Immunotherapy**

**Biologics**

**Allergy Immunotherapy Market Indication****Outlook**

**Allergic Rhinitis**

**Allergic Asthma**

**Atopic Dermatitis**

**Food Allergies**

**Allergy Immunotherapy Market Patient Type****Outlook**

**Pediatric**

**Adult**

**Geriatric**

****

## Market Drivers

### Focus on Preventive Healthcare

The emphasis on preventive healthcare in Germany is emerging as a key driver for the Germany [Allergy Immunotherapy](https://www.marketresearchfuture.com/reports/allergy-immunotherapy-market-1517) Market. With a growing recognition of the importance of early intervention in managing allergies, healthcare providers are increasingly recommending immunotherapy as a preventive measure. This shift towards proactive healthcare strategies is likely to encourage more patients to consider immunotherapy before their conditions worsen. Additionally, public health campaigns aimed at reducing the burden of allergic diseases are expected to further promote the adoption of immunotherapy. As preventive healthcare continues to gain traction, the Germany Allergy Immunotherapy Market may experience significant growth.

### Increasing Awareness of Allergy Management

The growing awareness regarding allergy management in Germany appears to be a significant driver for the Germany Allergy Immunotherapy Market. Educational campaigns and initiatives by healthcare professionals have led to a better understanding of allergies and their treatment options. This heightened awareness is likely to encourage more individuals to seek immunotherapy as a viable treatment option. According to recent surveys, approximately 30% of the German population suffers from allergic conditions, which underscores the necessity for effective management strategies. As more patients become informed about the benefits of immunotherapy, the demand for these treatments is expected to rise, thereby propelling the growth of the Germany Allergy Immunotherapy Market.

### Government Support and Regulatory Framework

The German government has implemented various policies and regulations that support the development and accessibility of allergy immunotherapy. This regulatory framework is designed to ensure that patients have access to safe and effective treatments. The Germany Allergy Immunotherapy Market benefits from initiatives such as funding for research and development, as well as subsidies for patients undergoing immunotherapy. Furthermore, the European Medicines Agency has established guidelines that facilitate the approval process for new immunotherapy products, which may lead to an increase in available treatment options. This supportive environment is likely to foster innovation and growth within the market.

### Rising Incidence of Allergic Rhinitis and Asthma

The rising incidence of allergic rhinitis and asthma in Germany is a critical driver for the Germany Allergy Immunotherapy Market. Recent studies indicate that approximately 20% of the population suffers from allergic rhinitis, while asthma affects around 5% of adults. This increasing prevalence of respiratory allergies is likely to create a larger patient base seeking effective treatment options. Immunotherapy has been shown to provide long-term relief from symptoms, which may lead to a growing preference for these therapies among healthcare providers and patients alike. Consequently, the demand for allergy immunotherapy is expected to rise, further propelling the market.

### Technological Advancements in Treatment Delivery

Technological advancements in the delivery of allergy immunotherapy are poised to enhance the efficacy and convenience of treatments in the Germany Allergy Immunotherapy Market. Innovations such as sublingual immunotherapy and smart delivery devices are becoming increasingly prevalent. These advancements not only improve patient compliance but also reduce the risk of adverse reactions. The market is witnessing a shift towards more patient-friendly treatment options, which could potentially increase the uptake of immunotherapy. As a result, the integration of technology into treatment modalities may drive growth in the Germany Allergy Immunotherapy Market, making therapies more accessible and effective.

## Future Outlook

The Germany Allergy Immunotherapy Market is projected to grow at a 9.43% CAGR from 2024 to 2035, driven by increasing allergy prevalence, technological advancements, and rising consumer awareness.

**New opportunities:**

- Development of personalized immunotherapy solutions for specific allergens. Expansion of telehealth platforms for remote allergy consultations. Investment in AI-driven diagnostics for enhanced patient targeting.

By 2035, the market is expected to be robust, driven by innovation and increased accessibility.

## Segment Insights

### By Indication: Allergic Rhinitis (Largest) vs. Allergic Asthma (Fastest-Growing)

In the Germany Allergy Immunotherapy Market, the indication segments showcase varied distributions. [Allergic Rhinitis](https://www.marketresearchfuture.com/reports/allergic-rhinitis-market-1547) stands out as the largest segment, indicating its prevalence in the population. Following closely is Allergic Asthma, which has been gaining momentum over recent years due to increased awareness and diagnosis rates. [Atopic Dermatitis](https://www.marketresearchfuture.com/reports/atopic-dermatitis-market-1610) and Food Allergies, while important, capture a smaller share of the market, demonstrating the segmented nature of allergy-related health issues among the population.

Allergic Rhinitis (Dominant) vs. Allergic Asthma (Emerging)

Allergic Rhinitis remains the dominant indication within the Germany Allergy Immunotherapy Market, driven by high incidence rates and significant public health focus. Its well-established treatment modalities contribute to a robust market position. Conversely, Allergic Asthma is emerging as a rapidly growing segment, propelled by expanding clinical evidence and advancements in immunotherapy treatments. The rising awareness of asthma as a chronic condition is fostering an upward trend in this segment, attracting a diverse range of treatment options and innovations in therapy.

### By Type of Immunotherapy: Subcutaneous Immunotherapy (Largest) vs. Sublingual Immunotherapy (Fastest-Growing)

In the Germany Allergy Immunotherapy Market, the distribution of market share among the different types of immunotherapy reveals that Subcutaneous Immunotherapy holds the largest proportion. This segment has established itself as a preferred choice due to its long-standing history and extensive clinical usage. Following closely is Sublingual Immunotherapy, which has been gaining traction among patients seeking convenience and ease-of-use, particularly in outpatient settings. Meanwhile, Oral and Intranasal Immunotherapy are smaller yet significant segments that cater to specific patient needs and preferences. Growth trends in the Germany Allergy Immunotherapy Market are being primarily driven by the rising prevalence of allergic conditions, coupled with increased awareness and acceptance of immunotherapy treatments. Innovations in delivery methods and formulations are also enhancing patient compliance and treatment outcomes. While Subcutaneous Immunotherapy continues to dominate, Sublingual Immunotherapy is on an upward trajectory, with more patients recognizing its benefits, marking a shift towards less invasive treatment options in the market.

Subcutaneous Immunotherapy (Dominant) vs. Sublingual Immunotherapy (Emerging)

Subcutaneous Immunotherapy is regarded as the dominant segment in the German Allergy Immunotherapy Market, characterized by its established protocols and a comprehensive track record of effectiveness. This method involves administering allergens via injections, which allows for precise dosage control and has shown significant efficacy in desensitizing patients over time. On the other hand, Sublingual Immunotherapy, as an emerging segment, is rapidly gaining popularity due to its non-invasive nature and improved patient convenience. By delivering allergen extracts under the tongue, it offers an alternative that is more acceptable for those averse to needles. Both segments are vital in addressing the growing demand for effective allergy treatments, yet they cater to different patient preferences and lifestyles.

### By Administration Route: Injection (Largest) vs. Sublingual (Fastest-Growing)

In the Germany Allergy Immunotherapy Market, the administration route segment reveals a notable distribution among different techniques. Injection therapy dominates the market, accounting for a significant share as it has been the traditional method for delivering immunotherapies for years. Sublingual immunotherapy, on the other hand, is rapidly gaining traction amongst patients and prescribers alike, reflecting a shifting preference towards less invasive options that maintain efficacy without the discomfort of needles. The growth trends within this segment are defined by increasing patient demand for convenience and reduced side effects associated with alternative administration routes. The rise of digital health and telemedicine has also led to a greater awareness of sublingual and oral routes, enabling better patient engagement. Factors such as advancements in formulations and clinical evidence supporting the effectiveness of sublingual therapies are driving their popularity in the German market.

Injection (Dominant) vs. Oral (Emerging)

The injection route remains the dominant delivery method in the Germany Allergy Immunotherapy Market, favored for its established efficacy and safety profile. Patients receiving injection therapy often benefit from a streamlined treatment regimen that allows for controlled dosing directly related to their allergies. In contrast, oral immunotherapy is emerging as a viable alternative, particularly appealing to patients who prefer a more convenient and less invasive option. With ongoing clinical studies and regulatory approvals, oral therapies are gaining acceptance, buoyed by their potential for home administration, thus reducing the need for frequent clinical visits. The trend toward patient-centered care is likely to solidify the presence of both these administration routes in the market, catering to diverse patient needs.

### By Patient Demographics: Pediatric (Largest) vs. Geriatric (Fastest-Growing)

In the Germany Allergy Immunotherapy Market, the patient demographics segment showcases a diverse distribution of market share across various categories. The pediatric segment accounts for the largest share, driven by increasing allergy incidences among children, as well as growing awareness among parents regarding effective treatments. Adult demographics also play a significant role, especially considering the higher exposure to allergens in urban settings. Meanwhile, the geriatric segment is witnessing a rapidly increasing share due to the rising prevalence of allergies among older adults, which is exacerbated by age-related factors such as immune system changes. The growth trends in the patient demographics segment can largely be attributed to the changing lifestyle patterns and increased outdoor exposure that heighten allergy risks. The pediatric segment is supported by proactive healthcare initiatives and preventative strategies aimed at reducing allergy onset in children. For geriatric patients, the growth is propelled by a growing focus on personalized healthcare and therapies that cater to age-specific needs. The continuous advancement in allergy immunotherapy solutions further aids in enhancing patient compliance, particularly amongst older demographics, contributing to the overall expansion of this market segment.

Pediatric (Dominant) vs. Geriatric (Emerging)

The pediatric segment remains dominant in the Germany Allergy Immunotherapy Market, benefitting from a proactive approach towards allergic conditions in children, leading to early diagnosis and treatment. This segment is characterized by a robust interest from parents seeking effective immunotherapy options for their children, significantly contributing to its prevailing market position. In contrast, the geriatric demographic is emerging rapidly, highlighting a shift in therapeutic focus as the older population experiences increased allergic disorders. Factors such as prolonged exposure to allergens and the aging immune system play pivotal roles in this growth. Healthcare providers are developing tailored interventions to address specific needs of both segments. The contrasting yet complementary nature of these two demographics underscores the evolving landscape of allergy treatments in Germany.

## Competitive Benchmarking

The Germany Allergy Immunotherapy Market is characterized by a dynamic competitive landscape, driven by increasing prevalence of allergic conditions and a growing awareness of immunotherapy as a viable treatment option. Key players such as Allergopharma (DE), Boehringer Ingelheim (DE), and Merck KGaA (DE) are strategically positioned to leverage innovation and expand their market presence. Allergopharma (DE) focuses on developing personalized immunotherapy solutions, while Boehringer Ingelheim (DE) emphasizes research and development to enhance treatment efficacy. Merck KGaA (DE) is actively pursuing partnerships to bolster its product portfolio, indicating a collective strategy among these companies to enhance competitive advantage through innovation and collaboration.
The market structure appears moderately fragmented, with several players vying for market share. Key business tactics include localizing manufacturing to reduce costs and optimize supply chains, which is crucial in maintaining competitive pricing. The influence of major players is significant, as their operational strategies shape market dynamics and consumer choices, fostering a competitive environment that encourages continuous improvement and innovation.
In January 2026, Allergopharma (DE) announced the launch of a new line of sublingual immunotherapy products aimed at enhancing patient compliance and treatment outcomes. This strategic move is likely to strengthen its market position by addressing the growing demand for convenient and effective allergy treatments. The introduction of these products may also reflect a broader trend towards patient-centric solutions in the immunotherapy sector.
In December 2025, Boehringer Ingelheim (DE) entered into a collaboration with a leading biotechnology firm to develop next-generation immunotherapy treatments. This partnership is expected to accelerate the development of innovative therapies, potentially positioning Boehringer Ingelheim (DE) as a frontrunner in the market. The collaboration underscores the importance of strategic alliances in fostering innovation and expanding therapeutic options for patients.
In November 2025, Merck KGaA (DE) expanded its research facilities in Germany, focusing on advanced immunotherapy research. This investment signifies a commitment to enhancing its R&D capabilities, which may lead to the development of novel therapies that could redefine treatment paradigms in allergy management. Such strategic investments are indicative of a long-term vision to maintain leadership in the competitive landscape.
As of February 2026, current trends in the Germany Allergy Immunotherapy Market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence in treatment development. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, suggesting a transformative phase for the market.

## Recent News & Developments

_In recent months, the Germany Allergy Immunotherapy Market has seen significant developments, particularly with companies like BioNTech SE and Novartis AG making strides in research and product offerings. In September 2023, Allergopharma GmbH & Co. KG expanded its portfolio with new immunotherapy products aimed at treating food allergies. Additionally, Merck KGaA announced advancements in biologics designed to enhance the efficacy of treatments for allergic diseases in August 2023. The market is also experiencing increased competition__,__with Stallergenes Greer and GlaxoSmithKline plc significantly investing in Research and Development to innovate their immunotherapy solutions. In terms of mergers, TheraBurst and Rhinopharma are reportedly in talks to consolidate their market positions, with discussions ongoing since October 2023. This consolidation trend reflects a larger movement in the sector to streamline operations and enhance treatment offerings for patients. Furthermore, as of 2022, the market valuation has shown robust growth, attributed to rising allergy incidences and increasing awareness about immunotherapy benefits among patients and healthcare providers in Germany. The focus on tailoring therapies to individual needs has also gained momentum, driving a new wave of product development in the sector._

## Report Scope

Report Scope:

| Report Attribute/Metric Source: | Details |
| --- | --- |
| MARKET SIZE 2018 | 266.0(USD Million) |
| MARKET SIZE 2024 | 285.5(USD Million) |
| MARKET SIZE 2035 | 571.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.504% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | BioNTech SE, Stallergenes Greer, TheraBurst, Immunovative Therapies Ltd, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Allergy Therapeutics plc, Rhinopharma, Anergis SA, Merck KGaA, Aimmune Therapeutics Inc., Mylan N.V., Allergopharma GmbH & Co. KG, UCB S.A. |
| SEGMENTS COVERED | Type, Product, Indication, Patient Type |
| KEY MARKET OPPORTUNITIES | Rising prevalence of allergic diseases, Increased investment in research, Growth of personalized medicine approaches, Advancements in delivery technologies, Expanding telehealth services for patients |
| KEY MARKET DYNAMICS | Increasing allergy prevalence, Advancements in immunotherapy, Growing awareness and education, Regulatory support and approvals, Rise in personalized medicine |
| COUNTRIES COVERED | Germany |

## Frequently Asked Questions

**Q: What is the current valuation of the Germany Allergy Immunotherapy Market?**
A: As of 2024, the market valuation was 277.34 USD Million.

**Q: What is the projected market size for the Germany Allergy Immunotherapy Market by 2035?**
A: The market is projected to reach 747.45 USD Million by 2035.

**Q: What is the expected CAGR for the Germany Allergy Immunotherapy Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during this period is 9.43%.

**Q: Which segments are included in the Germany Allergy Immunotherapy Market by indication?**
A: The market segments by indication include Allergic Rhinitis, Allergic Asthma, Atopic Dermatitis, and Food Allergies.

**Q: What were the market values for Allergic Rhinitis and Allergic Asthma in 2024?**
A: In 2024, the market values were 111.0 USD Million for Allergic Rhinitis and 70.0 USD Million for Allergic Asthma.

**Q: How does the market for Intranasal Immunotherapy compare to other types in 2024?**
A: In 2024, Intranasal Immunotherapy had a market value of 117.34 USD Million, indicating strong performance compared to other types.

**Q: What are the key players in the Germany Allergy Immunotherapy Market?**
A: Key players include Allergopharma, Boehringer Ingelheim, Merck KGaA, and ALK-Abello, among others.

**Q: What is the market segmentation by administration route in the Germany Allergy Immunotherapy Market?**
A: The market is segmented by administration route into Injection, Sublingual, Oral, and Intranasal.

**Q: What were the market values for Pediatric and Adult demographics in 2024?**
A: In 2024, the market values were 50.0 USD Million for Pediatric and 150.0 USD Million for Adult demographics.

**Q: What is the future outlook for the Germany Allergy Immunotherapy Market?**
A: The market is expected to grow significantly, reaching 747.45 USD Million by 2035, driven by increasing demand and innovation.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/germany-allergy-immunotherapy-market-56293*